Grobholz R, Hacker H J, Thorens B, Bannasch P
Abteilung für Cytopathologie, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Cancer Res. 1993 Sep 15;53(18):4204-11.
Expression of two important glucose transporter proteins, GLUT 2 (which is the typical glucose transporter in hepatocytes of adult liver) and the erythroid/brain type glucose transporter GLUT 1 (representing the typical glucose transporter in fetal liver parenchyma), was studied immunocytochemically during hepatocarcinogenesis in rats at different time points between 7 and 65 wk after cessation of 7-wk administration of 12 mg/kg of body weight of N-nitrosomorpholine p.o. (stop model). Foci of altered hepatocytes excessively storing glycogen (GSF) and mixed cell foci (MCF) composed of both glycogenotic and glycogen-poor cells were present at all time points studied. Seven wk after withdrawal of the carcinogen, GSF were the predominant type of focus of altered hepatocytes. Morphometrical evaluation of the focal lesions revealed that the number and volume fraction of GSF increased steadily until Wk 65. MCF were rare at 7 wk, increased slightly in number and size until Wk 37, but showed a pronounced elevation in their number and volume fraction from Wk 37 to Wk 65. In both GSF and MCF, GLUT 2 was generally decreased or partially absent at all time points. Consequently, foci of decreased GLUT 2 expression showed a steady increase in number and volume fraction from Wk 7 to Wk 65. GLUT 1 was lacking in GSF but occurred in some MCF from Wk 50 onward. The liver type glucose transporter GLUT 2 was decreased in all adenomas and hepatocellular carcinomas (HCC). In three of seven adenomas and 10 of 12 carcinomas, expression of GLUT 1 was increased compared with normal liver parenchyma. In two cases of adenoid HCC, cells of ductular formations coexpressed GLUT 2 and GLUT 1. In contrast, normal bile ducts, bile duct proliferations, and cystic cholangiomas expressed only GLUT 1. Seven of 12 HCC contained many microvessels intensely stained for GLUT 1, a phenomenon never observed in normal liver. Whenever adenoid tumor formations occurred, GLUT 1-positive microvessels were located in the immediate vicinity of these formations. Only in one HCC were such microvessels found in the absence of adenoid formations. Our studies indicate that a reduction of GLUT 2 expression occurs already in early preneoplastic hepatic foci and is maintained throughout hepatocarcinogenesis, including benign and malignant neoplasms. Reexpression of GLUT 1, however, appears in a few MCF and in the majority of adenomas and carcinomas.
在大鼠肝癌发生过程中,于口服给予12mg/kg体重的N-亚硝基吗啉7周后停药(停药模型),在7至65周的不同时间点,采用免疫细胞化学方法研究了两种重要的葡萄糖转运蛋白,即GLUT 2(成体肝脏肝细胞中的典型葡萄糖转运蛋白)和红系/脑型葡萄糖转运蛋白GLUT 1(代表胎儿肝实质中的典型葡萄糖转运蛋白)的表达情况。在所有研究时间点均存在过度储存糖原的肝细胞改变灶(GSF)以及由糖原丰富和糖原缺乏细胞组成的混合细胞灶(MCF)。致癌物撤药7周后,GSF是肝细胞改变灶的主要类型。对病灶性病变的形态计量学评估显示,GSF的数量和体积分数持续稳定增加直至65周。MCF在7周时罕见,数量和大小略有增加直至37周,但从37周至65周其数量和体积分数显著升高。在GSF和MCF中,GLUT 2在所有时间点通常均降低或部分缺失。因此,GLUT 2表达降低的病灶数量和体积分数从7周至65周持续稳定增加。GLUT 1在GSF中缺失,但从50周起在一些MCF中出现。肝型葡萄糖转运蛋白GLUT 2在所有腺瘤和肝细胞癌(HCC)中均降低。在7个腺瘤中的3个以及12个癌中的10个中,与正常肝实质相比,GLUT 1的表达增加。在两例腺样HCC中,小胆管形成的细胞共表达GLUT 2和GLUT 1。相反,正常胆管、胆管增生和胆囊胆管瘤仅表达GLUT 1。12个HCC中有7个含有许多GLUT 1染色强烈的微血管,这一现象在正常肝脏中从未观察到。每当出现腺样肿瘤形成时,GLUT 1阳性微血管位于这些形成物的紧邻区域。仅在一个HCC中,在没有腺样形成的情况下发现了此类微血管。我们的研究表明,GLUT 2表达降低在早期癌前肝病灶中就已出现,并在整个肝癌发生过程中持续存在,包括良性和恶性肿瘤。然而,GLUT 1的重新表达出现在少数MCF以及大多数腺瘤和癌中。